EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Randomisierte kontrollierte StudieOpen Access · CC BY-NC 4.0

Efficacy and safety of sarilumab in patients with rheumatoid arthritis stratified by age (<65 and ≥65 years): A post hoc analysis of Japanese Phase 3 clinical trials

Yoshiya Tanaka iD, Toshiya Takahashi, Hubert van Hoogstraten, Naoto Kato, Hideto Kameda iD

Modern Rheumatology · 2024

DOI: 10.1093/mr/roae057 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Modern Rheumatology, 2024. Verfasst von Yoshiya Tanaka und 4 weiteren Autor:innen. Beteiligte Einrichtung: The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health Japan, Fukuoka, Japan. Hauptthemen laut MEDLINE: Arthritis, Rheumatoid, Antirheumatic Agents, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

This study aimed to assess the efficacy and safety of sarilumab in older patients with active rheumatoid arthritis (RA).

Methods

This is a post hoc analysis of KAKEHASI (NCT02293902) and HARUKA (NCT02373202) trials with stratification by age (<65 and ≥65 years). Patients with moderately to severely active RA were treated with sarilumab in combination with methotrexate or with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) or as monotherapy. The primary end points in KAKEHASI and HARUKA trials were the American College of Rheumatology 20% improvement criteria (ACR20) responses at Week 24 and safety, respectively. Secondary end points were other RA disease activity measures, including Clinical Disease Activity Index (CDAI).

Results

Approximately 20% of patients were aged ≥65 years in treatment arms across both trials, except the sarilumab + csDMARD arm (40%, 12/30). ACR20 response rates were similar between age groups across sarilumab treatment arms, and similar results were obtained for the CDAI scores. Safety profiles were similar between age groups except for a higher incidence of serious adverse events in patients aged ≥65 years in the sarilumab + methotrexate arm.

Conclusions

In Japanese patients with RA enrolled in Phase 3 studies for sarilumab, no clear difference in efficacy or safety was observed between patients aged <65 and ≥65 years.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Arthritis, RheumatoidAntirheumatic AgentsAntibodies, Monoclonal, HumanizedHumansAgedMaleFemaleMiddle AgedTreatment OutcomeJapanMethotrexateAge FactorsDrug Therapy, CombinationAdultSeverity of Illness IndexEast Asian People

Stichwörter der Autor:innen

Interleukin-6 antibodyJapanolder adultrheumatoid arthritissarilumab

Substanzen

sarilumabAntirheumatic AgentsAntibodies, Monoclonal, HumanizedMethotrexate

Autor:innen und Institutionen

  • The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health Japan, Fukuoka, Japan.
  • Medical Affairs Department, Asahi Kasei Pharma Corporation, Tokyo, Japan.
  • Global Medical Affairs, Sanofi USA, Bridgewater, NJ, United States.
  • Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Toho University, Tokyo, Japan.

ORCID-Profile: Yoshiya Tanaka, Hideto Kameda

Zitieren

APA

Tanaka, Y., Takahashi, T., van Hoogstraten, H., Kato, N., & Kameda, H. (2024). Efficacy and safety of sarilumab in patients with rheumatoid arthritis stratified by age (. Modern Rheumatology. https://doi.org/10.1093/mr/roae057

Vancouver

Tanaka Y, Takahashi T, van Hoogstraten H, Kato N, Kameda H. Efficacy and safety of sarilumab in patients with rheumatoid arthritis stratified by age (. Modern Rheumatology. 2024. doi:10.1093/mr/roae057

BibTeX
@article{Tanaka2024,
  author = {Tanaka, Yoshiya and Takahashi, Toshiya and van Hoogstraten, Hubert and Kato, Naoto and Kameda, Hideto},
  title = {Efficacy and safety of sarilumab in patients with rheumatoid arthritis stratified by age (},
  journal = {Modern Rheumatology},
  year = {2024},
  doi = {10.1093/mr/roae057}
}
Kostenlos starten →